Video

Dr. Alter Discusses Provenge MOA and Tolerability

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, discusses the mechanism of action (MOA) and tolerability of the immunotherapy Provenge (sipuleucel-T) in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

The product of the Provenge vaccine stimulates the immune system by activating t-cells to recognize prostate cancer cells. The vaccine is created from the patient’s own cells, which prevents it from being rejected by the body.

Provenge provides a well-tolerated active therapy. The response varies from patient-to-patient ranging from nominal to prolonged. A survival benefit for Provenge was derived from several controlled trials. The median survival benefit from the vaccine is 25.8 months, compared to 21.7 in control groups.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center